Skip to content
Screener

CareDx CDNA Total Equity

Total Equity at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$52.69B+4.3%
Natera, Inc. logo
Natera, Inc.NTRA
$1.82B+46.2%
Insight Molecular Diagnostics Inc. logo
Insight Molecular Diagnostics Inc.IMDX
-$10.69M-205%
Personalis, Inc. logo
Personalis, Inc.PSNL
$254.77M+22.9%
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
$1.05B-6.9%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$6.85B+2.6%

Other financials

Income statement

See full
Revenue$117.7M+39.0%
Operating income$1.2M+109%
Net income$2.8M+127%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$78.5M-12.1%
Total debt$24.5M-19.1%
Total assets$411.1M-16.0%

Cash flow

See full
Operating cash flow$4.3M+116%
CapEx$3.8M+134%
Free cash flow$514.0K+102%

Valuation

See full
Market cap$2.32B+218%
Enterprise value$2.26B+228%
P/S5.6×+3.5×

Profitability

See full
Gross margin65.5%
Operating margin-3.9%-18.3pp
Net margin-2%-19.9pp
FCF margin-0%0.0pp

Returns & leverage

See full
Return on equity-2.4%-21.9pp
Debt / equity0.1×0.0×
Current ratio3.4×-0.7×

Where this comes from

Reported directly by CareDx in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: CareDx’s 10-Q, filed April 28, 2026.

Filed
Apr 28, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001217234-26-000033
Line itemMarch 31, 2026December 31, 2025
Stockholders’ equity:
Preferred stock: $0.001 par value; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025
Common stock: $0.001 par value; 100,000,000 shares authorized at March 31, 2026 and December 31, 2025; 51,274,651 and 50,916,644 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively5150
Additional paid-in capital1,052,3061,043,925
Accumulated other comprehensive loss(6,272)(5,515)
Accumulated deficit(732,550)(735,359)
Total stockholders’ equity313,535303,101
Total liabilities and stockholders’ equity$411,062$413,228

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is CareDx's total equity?
CareDx (CDNA) reported total equity of $313.54M in Q1 2026.
How has CareDx's total equity changed year-over-year?
CareDx's total equity decreased by 17.3% year-over-year, from $379.35M to $313.54M.
What is the long-term trend for CareDx's total equity?
Over 5 years (2020 to 2025), CareDx's total equity has grown at a 1.8% compound annual growth rate (CAGR), from $277.68M to $303.1M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about CareDx's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude